These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7182198)

  • 21. [Drug treatment for portal hypertension due to cirrhosis].
    Lebrec D; Benhamou JP
    Gastroenterol Clin Biol; 1982; 6(6-7):542-8. PubMed ID: 6126417
    [No Abstract]   [Full Text] [Related]  

  • 22. Hemodynamic assessment of pharmacological response in the treatment of portal hypertension: a need to know.
    Grace ND
    Am J Gastroenterol; 2000 Aug; 95(8):1862-4. PubMed ID: 10950027
    [No Abstract]   [Full Text] [Related]  

  • 23. [Portal hypertension in the absence of liver cirrhosis and hepatic obstruction of the main vessels of the portal system (arteriovenous insufficiency of portal circulation)].
    Patsiora MD; Ershov IuA
    Khirurgiia (Mosk); 1980 Jan; (1):64-9. PubMed ID: 7392493
    [No Abstract]   [Full Text] [Related]  

  • 24. Long term effects of propranolol on portal pressure in cirrhotic patients.
    Orban-Schiopu AM; Popescu CR
    Rom J Gastroenterol; 2003 Mar; 12(1):25-30. PubMed ID: 12673376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of lisinopril and nebivolol therapy of portal hypertension and kidney dysfunction in patients with liver cirrhosis].
    Fedulenkova LV; Drozdov VN; Mikheeva OM; Petrakov AV
    Eksp Klin Gastroenterol; 2008; (5):37-41. PubMed ID: 19145915
    [No Abstract]   [Full Text] [Related]  

  • 26. [Hemodynamic disorders due to liver cirrhosis].
    Garbuzenko DV
    Klin Med (Mosk); 1996; 74(2):5-7. PubMed ID: 8772089
    [No Abstract]   [Full Text] [Related]  

  • 27. [Propranolol and portal hypertension in cirrhotic patients. Manometric and hemodynamic studies].
    Reding P; Urbain D; Frère D; Thys O; Grivegnée A
    Acta Gastroenterol Belg; 1986; 49(3):324-8. PubMed ID: 3825447
    [No Abstract]   [Full Text] [Related]  

  • 28. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
    Sookoian S; Castaño G; García SI; Viudez P; González C; Pirola CJ
    Am J Gastroenterol; 2005 Mar; 100(3):636-42. PubMed ID: 15743363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does losartan work after all?
    Blendis LM; Wong F
    Am J Gastroenterol; 2003 Jun; 98(6):1222-4. PubMed ID: 12818261
    [No Abstract]   [Full Text] [Related]  

  • 30. Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
    Wang H; Chen XP; Qiu FZ
    Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):391-6. PubMed ID: 14599946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
    Shah V
    J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Functional factors which contribute to portal hypertension in hepatic cirrhosis].
    Orrego Matte H
    Medicina (B Aires); 1970; 30(4):399-401. PubMed ID: 5487697
    [No Abstract]   [Full Text] [Related]  

  • 33. [Vasodilators and renal function in cirrhosis].
    Albillos A; Iborra J
    Gastroenterol Hepatol; 1995 Nov; 18(9):488-92. PubMed ID: 8521230
    [No Abstract]   [Full Text] [Related]  

  • 34. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension.
    Hernández-Guerra M; García-Pagán JC; Turnes J; Bellot P; Deulofeu R; Abraldes JG; Bosch J
    Hepatology; 2006 Mar; 43(3):485-91. PubMed ID: 16496307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
    Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
    Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hemodynamic status in liver cirrhosis with portal hypertension: a retrospective study on 49 patients].
    Maffezzoli GF; Pacini L; Tita M; Tramini MG; Benussi P; Pederzoli P; Serio G
    Chir Ital; 1986 Apr; 38(2):159-69. PubMed ID: 3742682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Arterial blood supply of the liver in portal hypertension and liver cirrhosis].
    Voegeli E
    Schweiz Med Wochenschr; 1971 May; 101(20):767. PubMed ID: 5578420
    [No Abstract]   [Full Text] [Related]  

  • 38. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-blockers.
    Bursey RF
    Can J Gastroenterol; 1998; 12(8):542-3. PubMed ID: 9926263
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.